Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset

Journal of Rheumatology

Volumn 36, Issue 1, 2009, Pages 68-75

  Romero Díaz, Juanita ^a   García Sosa, Icellini ^a   Sánchez Guerrero, Jorge ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Autoimmune diseases; Incidence; Systemic lupus erythematosus; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CHLOROQUINE;

ADULT; AGE DISTRIBUTION; ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DEATH; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DOPPLER FLOWMETRY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LOW DRUG DOSE; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIXED CONNECTIVE TISSUE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHLEBOGRAPHY; POLYMYOSITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SCLERODERMA; SJOEGREN SYNDROME; SPONDYLOARTHROPATHY; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; VASCULITIS; VEIN INSUFFICIENCY; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASES; COHORT STUDIES; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; YOUNG ADULT;

EID: 58149502452     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.071244     Document Type: Article

References (29)

1. Silman AJ, Hochberg MC. Systemic lupus erythematosus. In: Silman AJ, Hochberg MC, editors. Epidemiology of the rheumatic diseases. New York: Oxford University Press; 1993:163-91.
2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine Baltimore 2003;82:299-308.
3. Lowe GDO. Venous and arterial thrombosis: epidemiology and risk factors at various ages. Maturitas 2004;47:259-63.
4. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
5. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
6. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and the risk of pulmonary embolism in women. Lancet 1996;348:983-7.
7. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous and thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000;132:689-96.
8. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002;29:2531-6.
9. Brouwer JLP, Bijl M, Veeger NJGM, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004;104:143-8.
10. Sarabi ZS, Chang E, Bobba R, et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 2005;53:609-12.
11. Calvo-Alen J, Toloza SMA, Fernández M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005;52:2060-8.
12. Chang ER, Pineau CA, Bernatsky S, Neville C, Clarke AE, Fortin P. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. J Rheumatol 2006;33:1780-4.
13. Mok CC, Tang SSK, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus. A comparison of three ethnic groups. Arthritis Rheum 2005;52:2774-82.
14. Drenkard C, Villa AR, Alarcón-Segovia D, Pérez- Vázquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994;21:1067-72.
15. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004;164:77-82.
16. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005;131:417-30.
17. Tan EM, Cohen AS, Fries JF, et al. The 1982 American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
19. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
20. Tanimoto K, Nakano I, Kano S, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995;22:668-74. Erratum in: J Rheumatol 1995;22:1807.
21. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
22. Alarcon-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier; 1987:33-40.
23. Cats A, van der Linden SJ, Goei The HS, Khan MA. Proposals for diagnostic criteria of ankylosing spondylitis and allied disorders. Clin Exp Rheumatol 1987;5:167-71.
24. Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
25. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
26. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
27. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
28. Manzi S, Mailahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
29. Ho KT, Ahn CW, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology Oxford 2005;44:1303-7.